Treatment hyperphosphatemia in hemodialysis patient

The effect Nicotinamide supplementation on Hyperphosphatemia in Patients Undergoing Hemodialysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201011295275N1

Enrollment

Registered

2011-04-11

Start date

2010-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperphosphatemia in hemodialysis. Extracorporeal dialysis

Interventions

Intervention 1: Intervention 1 giveniacinamide at 500 mg/d (as 250 mg twice daily) to expermental group. Intervention 2: Intrevention 2 placibo give to control group During the 6-8week treament.

Treatment - Drugs

Placebo

Intervention 1 giveniacinamide at 500 mg/d (as 250 mg twice daily) to expermental group

Intrevention 2 placibo give to control group During the 6-8week treament.

Eligibility

Sex/Gender

All

Age

15 Years to 85 Years

Inclusion criteria

Inclusion criteria: include criteria: 1)age>15 2)phosphore>5.5 3)more than 6 month to beginning in hemodialysis exclude criteria: 1)patient refuse 2)drug adverse

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hyperphosphatemia. Timepoint: once two weeks. Method of measurement: serum phosphor checked.	—

Secondary

Measure	Time frame
HDL. Timepoint: Once two weeks. Method of measurement: HDL in serum checked.;PTH. Timepoint: Once two weeks. Method of measurement: PTH in serum checked.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoud Sefid Moye Azar

Tabriz University of Medical Sciences and Health Services

drtayebikh@tbzmed.ac.ir masoudsefid@gmail.com+98 41 1554 4854

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026